Glaxo JV Wins FDA Go-Ahead, Chesapeake Drops Four Execs, and 3 More Hot Stocks

  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

GlaxoSmithKline (NYSE:GSK): Glaxo’s joint venture, ViiV Healthcare, has won Food and Drug Administration approval for its once-daily HIV pill Tivicay, which was shown to reduce the HIV virus to undetectable levels in more people than Gilead’s (NASDAQ:GILD) Atripla, the world’s top-selling treatment for the segment. Glaxo has a 76.5 percent holding in ViiV, while Pfizer has 13.5 percent, and Japan’s Shionogi has 10 percent.


More Articles About:

To contact the reporter on this story: To contact the editor responsible for this story:

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business